We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
On May 23, the NMPA official website revealed that Aripiprazole (Aripiprazole long-acting intramuscular injection) developed by Otsuka Pharmaceutical to treat schizophrenia was approved for marketing.